Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Breast cancer, female
Stage/Subtype:  stage IIIA breast cancer
Trial Type:  Treatment
Results 1-25 of 221 for your search:
Start Over
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-302-02-02-03, NCI-2014-02093, NCT02213744
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer
Status: Active
Phase: Phase III
Type: Health services research, Treatment
Age: 18 and over
Trial IDs: S1007, NCI-2011-02623, CDR0000692475, PS1007_A11PAMDREVW01, SWOG-S1007, NCT01272037
Testosterone in Treating Postmenopausal Patients with Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: A221102, NCI-2012-00719, CDR0000730083, CALGB-A221102, NCCTG-N10C7, NCT01573442
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, S1207/NSABP B-53, SWOG-S1207, NCT01674140
A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: 18 and over
Trial IDs: GBG78/BIG 1-13/NSABP-B-54-I, NCI-2014-02553, 2013-001040-62, NCT01864746
Standard or Comprehensive Radiation Therapy in Treating Patients with Early-Stage Breast Cancer Previously Treated with Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NSABP-B-51, NCI-2012-03198, NSABP-B-51/RTOG-1304, NCT01872975
Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011202, NCI-2013-00875, NCT01901094
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 673-301, NCI-2014-00659, U1111-1155-7579, NCT01945775
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, B-55/BIG 6-13, BIG 6-13, D081CC00006, NSABP B-55/BIG 6-13, NCT02032823
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over, postmenopausal if female
Trial IDs: CBYL719C2301, NCI-2015-01171, 2015-000340-42, NCT02437318
Platinum Based Chemotherapy or Capecitabine in Treating Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA1131, NCI-2014-01820, NCT02445391
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-BR003, NCI-2015-00128, NRG-BR1428, NCT02488967
RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: SPI-GCF-301, NCI-2016-00155, NCT02643420
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CP-MGAH22-04, NCI-2016-00295, NCT02492711
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 3475-355, NCI-2016-01555, 163422, 2016-001432-35, NCT02819518
Pembrolizumab in Treating Patients with Triple-Negative Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1418, NCI-2016-01595, S1418/BR006, NCT02954874
Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive Triple Negative Stage II-III Breast Cancer after Chemotherapy, Surgery, and/or Radiation Therapy
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 to 69
Trial IDs: A011502, NCI-2016-00233, NCT02927249
Proton Beam Radiation Therapy or Photon Beam Radiation Therapy in Treating Patients with Non-Metastatic Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: UPCC 19115, NCI-2015-01950, 823440, RTOG 3509, RTOG 3510, UPC 19115, NCT02603341
Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Postmenopausal Women With HR+ HER2- aBC
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011A2404, NCI-2016-01811, NCT02941926
Trastuzumab in Treating Leptomeningeal Metastases in Patients with HER2-Positive Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NU 10C03, NCI-2011-00110, STU00040150, STU00040150-MOD0003, NCT01325207
Eribulin Mesylate and Cyclophosphamide in Treating Patients With Solid Tumor Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 80
Trial IDs: 11996, NCI-2012-00436, NCT01554371
Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients with Stage IIB-IV Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 2011-269, NCI-2013-01311, 007884, 11-051, PTX-200, TCN-PM, NCT01697293
Start Over